Heart disease kills at least nearly one in three people worldwide, yet the drugs used to fight artery disease can miss the damaged area or harm other organs. This review explores a striking alternative: tiny carriers that may find the trouble and open their medicine there.

Cardiovascular disease caused at least thirty-one percent of global deaths, and atherosclerosis is one of its main causes. Standard treatment for atherosclerosis uses statins and other cholesterol-lowering drugs, but conventional approaches have low drug utilization and can injure non-target organs.

The proposed answer is to use tiny carriers for detection and drug delivery, aimed specifically at hardened artery damage. The review brings together how these carriers are built, what they target, what signals make them release their contents, and what treatment results have been reported.

The core idea is like sending a courier through a city with a damaged neighborhood marked on the map: the package travels through the body, finds the area in need, and delivers its contents there instead of dropping them everywhere. There are two broad ways to guide the carrier.

Damaged artery walls can be leaky, allowing carriers to collect there, or the carrier can be given a surface feature that binds to markers found in the diseased area. Active targeting can increase both the carrier’s gathering at the damaged site and the amount that arrives there, improving therapeutic efficiency.

Possible destinations include inflamed vessel cells, immune cells, the surrounding support material, muscle cells, and blood-clotting cells. Immune cells called macrophages adhere to and accumulate in the artery wall through scavenger receptors on their surfaces. Their scavenger receptor CD36 plays important roles in lipid metabolism and lipid uptake, helping explain why macrophages take up large amounts of fat.

Because macrophages influence artery disease from formation through plaque rupture, nanoparticles can target them to inhibit its development. The review describes carriers loaded with cholesterol-lowering or anti-clotting medicines, and with genetic instructions, that are directed toward these macrophages.

The goal is to slow the development of artery disease by acting on the cells that collect inside the plaque. One set of carriers attached specifically to the CD36 surface receptor on these macrophages. In mice, the carriers selectively bound to macrophages in artery plaques, and macrophage buildup in the plaques fell.

These tiny fat-based carriers are designed to recognize CD36 on artery-wall macrophages, the cells that gather harmful cholesterol and become foam cells. By concentrating treatment inside those cells, the approach aims to interrupt plaque growth where it begins.

Small-molecule medicine is encapsulated within nanocarriers, which maintain their structural integrity while traveling through normal, healthy tissues before reaching the lesion. At the lesion, specific stimuli trigger the nanocarriers to break down and release the drug, reducing systemic toxicity from small-molecule treatment.

Those conditions can include mild acidity, fast-moving blood, excess enzymes, or chemically reactive molecules. The carrier can be designed to respond to one of these local signals rather than releasing its medicine immediately. When the carrier reaches the lesion, specific stimuli can break down its structure and release the drug, helping reduce systemic toxicity from small-molecule treatment.

Other designs use outside controls, such as light or magnetic fields, or combine multiple stimuli to help trigger treatment. One reviewed treatment used a carrier that released its genetic treatment in endolysosomes after target cells took it inside. In mice, it accumulated in artery plaques and associated cells.

That treatment improved the movement of cholesterol out of cells and changed immune activity by regulating macrophages and T cells. In the mice, it reduced vulnerable artery plaques, the kind considered more likely to cause trouble. Another carrier released two treatments together when it encountered unusual acidity at the lesion.

One lowered damaging chemical activity, while the other reduced inflammation and limited the growth of cells involved in the plaque. A different design used a substance found in the artery environment to recognize inflamed macrophages and respond to an enzyme. Its carriers held more than twenty percent of their contents and showed strong enzyme-triggered release.

Laboratory tests confirmed that this carrier reached its intended cells and reduced inflammation, while causing little cell damage and remaining compatible with blood. Animal studies found that the carrier stayed in the bloodstream longer and showed favorable compatibility in the body during those studies.

Some carriers respond to more than one signal, combining local conditions inside the body with outside controls. The review says this multi-signal approach can improve targeting and the efficiency of drug delivery. But this area is still small: only a limited number of studies have examined carriers responding to several signals in artery disease.

Many of the reported designs combine light with a local chemical signal or an enzyme. Other designs combine acidity, the force of flowing blood, and reactive chemicals. These carriers are presented as promising, but the review does not treat that promise as settled clinical proof.

The review’s broader picture is a treatment that can remain in the body longer, delay release, and recognize the diseased site. Changing the carrier’s surface may help it avoid removal by the immune system and bind to markers that are unusually abundant in the lesion. These designs combine targeted drug delivery with delayed release, so one carrier can help determine both where medicine goes and when it opens.

For someone facing artery disease, that could mean delayed release, longer circulation, and more targeted delivery, aiming for efficient treatment with lower toxicity. The central idea is targeted, trigger-controlled delivery: a tiny carrier reaches artery damage, recognizes its surroundings or a specific cell, and releases treatment there.

The studies reviewed suggest this could make treatment more focused, but the evidence remains mainly preclinical.